Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Danone Sa
DANONE: 2025: Another year of strong delivery
Business
Feb 20 2026
30 min read

DANONE: 2025: Another year of strong delivery

news images

2025 Full-Year Results
Press release – Paris, February 20, 2026 at 7:30am CET

2025: Another year of strong delivery

  • FY 2025 sales of €27,283m up +4.5% on a like-for-like (LFL) basis, with volume/mix up +2.7%, and price up +1.8%

  • Q4 sales up +4.7% LFL, driven again by strong volume/mix, up +2.5%, and price up +2.1%

    • Sustained momentum in Europe, driven by continued progress in EDP and solid performance in Adult Medical Nutrition and Waters

    • Soft Q4 performance in North America, despite sustained momentum in High Protein and a solid Specialized Nutrition performance

    • Closing a year of exceptional performance in China, North Asia & Oceania with strong Q4 in Specialized Nutrition and EDP

  • Recurring operating margin up +44 basis points (bps) at 13.4% driven by further improvement in margin from operations while continuing to reinvest into future growth

  • Recurring EPS up +4.6% to €3.80

  • €2.8bn Free cash flow, reflecting strong operating performance

  • Proposed dividend up +4.7% to €2.25

  • Recognized global sustainability leadership: CDP ‘Triple A’ List and worldwide B Corp certification

  • 2026 guidance in line with mid-term ambition: like-for-like sales growth expected between +3% and +5%, with recurring operating income growing faster than sales


Full-Year 2025 Key Figures


in millions of euros unless stated otherwise

FY 2024

FY 2025

Reported change

Like-for-like
change (LFL)

Sales

27,376

27,283

-0.3%

+4.5%

Recurring operating income

3,558

3,665

+3.0%

 

Recurring operating margin

13.0%

13.4%

+44 bps

 

Non-recurring operating income and expenses

(179)

(725)

(546)

 

Operating income

3,379

2,940

-13.0%

 

Operating margin

12.3%

10.8%

-157 bps

 

Recurring net income – Group share

2,345

2,461

+5.0%

 

Non-recurring net income – Group share

(324)

(636)

(313)

 

Net income – Group share

2,021

1,825

-9.7%

 

Recurring diluted EPS (€)

3.63

3.80

+4.6%

 

EPS (€)

3.13

2.82

-10.1%

 

Cash flow from operating activities

3,831

3,779

-1.3%

 

Free cash flow

3,003

2,799

-6.8%

 

1

Antoine de Saint-Affrique: CEO statement

In 2025, we again delivered broadbased, quality growth, reaffirming the strength and resilience of our healthfocused portfolio. Likeforlike sales grew +4.5%, driven by positive volume/mix and supported by our multi-engine growth model.

All categories and geographies contributed, with strong momentum in China, North Asia & Oceania, and sustained progress in Europe. We continued to perform, expand our recurring operating margin, improve ROIC and generate strong free cash flow, while transforming the company and reinvesting in capabilities, science, and innovation.

As we advance Chapter 2 of Renew Danone, we are reshaping our portfolio: scaling U.S. Medical Nutrition, strengthening our dairy strongholds, advancing microbiome science, and accelerating digitalization. Yet we remain clear-eyed: there is more to do and some areas still require further progress.

Looking ahead to 2026, in a world that remains volatile, we remain disciplined and fully committed to our science-based and consumer and patient centric approach. We enter the year with confidence, aligned with the mid-term ambition we have set out.

I. FOURTH QUARTER AND FULL-YEAR RESULTS

Fourth quarter and full-year sales

In Q4 2025, sales stood at €6,684m, up +4.7% LFL, with an increase of +2.5% from volume/mix and +2.1% from price. On a reported basis, sales decreased by -0.5%, negatively impacted by forex and others
(-6.3%), mainly reflecting the depreciation of several currencies against the euro, notably the US dollar, the Argentine peso and the Chinese renminbi. In addition, scope (+0.8%) and hyperinflation (+0.4%) both contributed positively to reported sales.

In 2025, sales stood at €27,283m, up +4.5% LFL, led by an increase of +2.7% from volume/mix and +1.8% from price. On a reported basis, sales were broadly stable (-0.3%), mainly due to the negative impact from forex and others
(-5.0%), while hyperinflation contributed positively (+0.6%) and scope negatively (-0.4%).

Sales by operating segment

€ million except %

Q4
2024

Q4
2025

Reported change

LFL sales
growth

Volume/mix growth

FY
2024

FY
2025

Reported change

LFL sales
growth

Volume/mix
growth

 

BY GEOGRAPHICAL ZONE

 

 

 

 

 

 

 

 

 

 

Europe

2,358

2,404

+1.9%

+2.5%

+1.0%

9,568

9,779

+2.2%

+2.3%

+1.9%

 

North America

1,636

1,560

-4.7%

+0.7%

-0.5%

6,579

6,316

-4.0%

+2.0%

+0.6%

 

China, North Asia & Oceania

886

904

+2.1%

+10.4%

+10.6%

3,694

3,953

+7.0%

+11.7%

+12.4%

 

Latin America

724

723

-0.1%

+8.3%

+0.1%

3,029

2,792

-7.8%

+6.0%

-1.8%

 

Asia, Middle East & Africa

1,112

1,093

-1.7%

+8.3%

+5.5%

4,506

4,444

-1.4%

+5.6%

+2.1%

 

BY CATEGORY

 

 

 

 

 

 

 

 

 

 

EDP

3,355

3,288

-2.0%

+3.8%

+1.6%

13,463

13,158

-2.3%

+3.5%

+1.7%

 

Specialized Nutrition

2,308

2,372

+2.8%

+7.2%

+5.4%

8,936

9,277

+3.8%

+7.4%

+5.5%

 

Waters

1,053

1,023

-2.8%

+2.2%

-0.5%

4,977

4,848

-2.6%

+1.9%

+0.3%

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL

6,716

6,684

-0.5%

+4.7%

+2.5%

27,376

27,283

-0.3%

+4.5%

+2.7%

 

Europe delivered sustained momentum in Q4 2025 with the 9th consecutive quarter of positive volume/mix; sales were up +2.5% LFL, with volume/mix at +1.0% and price at +1.5%. EDP continued its progress with double-digit growth in High-Protein and Activia returned to growth across the region. Specialized Nutrition was driven by strong performance in Adult Medical Nutrition while momentum was also strong in Waters.

In North America, Q4 sales were up +0.7% LFL, with volume/mix down -0.5% and price up +1.3%. In EDP, High-Protein continued to grow at a double-digit pace, while the rest of the yogurt portfolio remains work in progress. Coffee Creamers are progressively regaining competitiveness, with innovation launched in the “clean label” segment during the period, while STōK cold brew coffee brand is thriving. Specialized Nutrition delivered a strong performance, from both Kate Farms and the legacy Nutricia businesses.

China, North Asia & Oceania delivered another quarter of strong growth in Q4, with sales up +10.4% LFL, led by volume/mix at +10.6%, with price at -0.2%. Specialized Nutrition continued to grow strongly, equally driven by Infant Milk Formula and Medical Nutrition. EDP delivered a remarkable performance in Japan, led by functional brands Activia (Bio) and Oikos. In Waters, the team began preparations for the 2026 season after a solid 2025.

Latin America delivered strong LFL sales growth of +8.3% in Q4, with volume/mix at +0.1% and price at +8.2%. EDP posted strong competitive growth across the region, supported by the Danone brand and High Protein platforms. Specialized Nutrition maintained strong momentum, driven by double‑digit growth in Aptamil and a solid contribution from the Medical Nutrition portfolio. In Waters, performance returned to growth after a challenging 2025 season, which was impacted by adverse weather.

In Asia, Middle East & Africa (AMEA), Q4 sales increased by +8.3% LFL, led by volume/mix at +5.5% and price up +2.8%. Dairy Africa benefited from a sustained momentum with positive volume/mix. Specialized Nutrition delivered double-digit growth, driven by good performance of Aptamil across geographies, including strong competitive growth in India.

Sales by geography by category

Q4 2025

Europe

North America

China, North Asia & Oceania

AMEA &
Latin America

Total

Sales (€m)

LFL sales growth (%)

Sales (€m)

LFL sales growth (%)

Sales (€m)

LFL sales growth (%)

Sales (€m)

LFL sales growth (%)

Sales (€m)

LFL sales growth (%)

 

 

 

 

 

 

 

 

 

 

 

EDP

1,102

+3.0%

1,355

+0.3%

103

+19.5%

728

+10.3%

3,288

+3.8%

Specialized Nutrition

818

+0.6%

139

+10.3%

721

+10.4%

695

+11.3%

2,372

+7.2%

Waters

484

+4.8%

66

-1.6%

81

+0.1%

393

+0.4%

1,023

+2.2%

Total

2,404

+2.5%

1,560

+0.7%

904

+10.4%

1,816

+8.3%

6,684

+4.7%


FY 2025

Europe

North America

China, North Asia & Oceania

AMEA &
Latin America

Total

Sales (€m)

LFL sales growth (%)

Sales (€m)

LFL sales growth (%)

Sales (€m)

LFL sales growth (%)

Sales (€m)

LFL sales growth (%)

Sales (€m)

LFL sales growth (%)

 

 

 

 

 

 

 

 

 

 

 

EDP

4,394

+2.0%

5,554

+1.7%

407

+12.8%

2,803

+8.5%

13,158

+3.5%

Specialized Nutrition

3,217

+2.1%

464

+6.6%

2,768

+13.2%

2,828

+8.1%

9,277

+7.4%

Waters

2,168

+3.3%

299

+2.6%

777

+6.1%

1,605

-1.9%

4,848

+1.9%

Total

9,779

+2.3%

6,316

+2.0%

3,953

+11.7%

7,236

+5.8%

27,283

+4.5%

Recurring operating margin

Recurring operating income (€m) and margin (%)

FY 2024

FY 2025

Reported
change

€m

Margin (%)

€m

Margin (%)



BY GEOGRAPHICAL ZONE

 

 

 

 

 

 

Europe

1,143

11.9%

1,178

12.0%

+10 bps

North America

749

11.4%

694

11.0%

-39 bps

China, North Asia & Oceania

1,086

29.4%

1,154

29.2%

-19 bps

Latin America

113

3.7%

179

6.4%

+267 bps

Asia, Middle East & Africa

468

10.4%

460

10.4%

-2 bps



BY CATEGORY

 

 

 

 

 

 

EDP

1,142

8.5%

1,121

8.5%

+4 bps

Specialized Nutrition

1,842

20.6%

2,016

21.7%

+112 bps

Waters

574

11.5%

528

10.9%

-64 bps

 

 

 

 

 

 

 

Total

3,558

13.0%

3,665

13.4%

+44 bps

Danone posted recurring operating income of €3,665m in 2025. Recurring operating margin stood at 13.4%, up +44 bps compared to last year. This increase was mainly led by the improvement in margin from operations (+77 bps). Danone continued to reinvest in A&P, product superiority and capabilities for -59 bps. Finally, Overheads before reinvestments had a relatively neutral impact (-3 bps), while Other effects had a combined impact of +29 bps, mainly related to IAS 29.

Net income and Earnings per share

 

FY 2024

FY 2025

 

 

in millions of euros unless stated otherwise

Recurring

Non-recurring

Total

 

Recurring

Non-recurring

Total

 

 

Operating income

3,558

(179)

3,379

 

3,665

(725)

2,940

 

 

Cost of net financial debt

(197)

 

(197)

 

(197)

 

(197)

 

 

Other financial income and expense

(108)

(75)

(183)

 

(111)

(96)

(207)

 

 

Income before tax

3,253

(254)

2,999

 

3,357

(821)

2,536

 

 

Income tax

(888)

(41)

(929)

 

(906)

166

(741)

 

 

Effective tax rate

27.3%

 

31.0%

 

27.0%

 

29.2%

 

 

Net income from fully consolidated companies

2,365

(295)

2,070

 

2,450

(655)

1,795

 

 

Share of profit (loss) of equity-accounted companies

76

(46)

30

 

108

(16)

92

 

 

Net income

2,441

(340)

2,100

 

2,558

(671)

1,887

 

 

Group share

2,345

(324)

2,021

 

2,461

(636)

1,825

 

 

• Non-controlling interests

96

(17)

79

 

97

(34)

63

 

 

Diluted EPS (€)

3.63

 

3.13

 

3.80

 

2.82

 

Recurring EPS increased by +4.6% to €3.80, mostly driven by strong operational performance.

Non-recurring operating income and expense reached -€725 million in 2025, including one-off costs related to transformation projects, mainly in Europe and Indonesia, and the impairment of intangible assets. This compares to -€179 million in 2024, which included the gains on disposal related to EDP business in Russia, Horizon Organic and Wallaby, and Michel & Augustin. As a result, Reported EPS stood at €2.82 in 2025, down -10.1%.
Cash flow and Debt

Free cash flow reached €2,799 million in 2025, compared to the record level of €3,003 million in 2024. Capex increased by €132 million compared to last year, at -€1,055 million. Working Capital stood at a record -10.2% of sales (163bps improvement) and change in working capital contributed positively to free cash flow generation (+€276 million) although to a lower extent than the exceptional 2024 contribution (+€534 million).

As of December 31, 2025, Danone’s net debt stood at €8.4 billion, improving from €8.6 billion last year, reflecting mainly the strong free cash flow generation.

Dividend

At the Annual Shareholders’ Meeting on April 23, 2026, Danone’s Board of Directors will propose a dividend of €2.25 per share in respect of the 2025 fiscal year, up +4.7% compared to previous year. Assuming this proposal is approved, the ex-dividend date will be May 4, 2026, and the dividend will be payable on May 6, 2026.

II. RECENT DEVELOPMENTS IN INFANT FORMULA

Danone stands for quality and food safety, and its absolute priority is to ensure that parents and healthcare professionals continue to place their trust in its brands.

Danone always takes action to comply with new requirements.

In light of the sector situation, the requirements of national food safety authorities continue to evolve. As a responsible manufacturer and to abide by this ongoing evolution, Danone has been recalling, from relevant markets, batches of infant formula products.

Whilst recall processes are underway in coordination with authorities, the current financial impacts identified are not material. Impact assessment will be finalized once the recalls have been completed.

III. 2026 GUIDANCE

2026 guidance in line with mid-term ambition: like-for-like sales growth expected between +3% and +5%, with recurring operating income growing faster than sales.

IV. RECENT MAJOR DEVELOPMENTS

  • February 12, 2026: Danone acquired an additional 1% stake in its Australian Dairy joint-venture with Saputo after exercising its call option, bringing its ownership up to 51%. This will result in the financial consolidation of this business.

  • January 23, 2026: In context of evolving authorities’ guidance, Danone announced targeted recall of specific infant formula batches.

  • January 8, 2026: Danone has been recognized on the CDP ‘Triple A’ List for 2025, underscoring its leadership in corporate transparency and performance on climate change, water stewardship, and forest preservation. This achievement reflects Danone’s commitment to rigorous disclosure and verified action on environmental topics.

  • December 17, 2025: As part of the simplification of its corporate structure, Danone SA purchased all 5,780,005 of its own shares previously held by its Spanish subsidiary, Danone Spain. This transaction has no impact on the total Danone shares held by the Group.

  • December 4, 2025: To offset the dilutive impact of its annual employee shareholder plans, Danone launched a buyback of 3.8 million shares, which was completed on December 18, 2025.

  • November 25, 2025: Danone officially achieved B Corp™ certification worldwide, becoming a global leader in B Corp™ certification at scale. With more than 200 legal Danone entities now certified in over 60 countries, Danone employees represent around 9% of the global B Corp™ movement workforce.

V. SHAREHOLDERS’ MEETING AND FINANCIAL STATEMENTS

At its meeting on February 19, 2026, the Board of Directors approved the draft resolutions that will be submitted to the approval of the Shareholders’ Meeting on April 23, 2026. In particular, the Board proposes that shareholders renew the term of office of Gilles Schnepp, Valérie Chapoulaud-Floquet and Sanjiv Mehta as Directors, whose current term of office will expire at the next Shareholders’ Meeting. It will also submit to the Shareholder’s Meeting resolutions, notably on the compensation of corporate officers, on share buy-backs and on employees share capital increases.

At its meeting on February 19, 2026, the Board of Directors approved the statutory and consolidated financial statements for the 2025 fiscal year. Regarding the audit process, as of today, the statutory auditors have substantially completed their examination of financial statements and verification of the sustainability information.

VI. ALTERNATIVE PERFORMANCE MEASURES NOT DEFINED BY IFRS

IAS 29: impact on reported data

Danone has applied IAS 29 in hyperinflationary countries, as defined in IFRS. Adoption of IAS 29 in hyperinflationary countries requires their non-monetary assets and liabilities and their income statement to be restated to reflect the changes in the general purchasing power of their functional currency, leading to a gain or loss on the net monetary position, included in the net income. Moreover, their financial statements are converted into euros using the closing exchange rate of the relevant period.

IAS 29: impact on reported data
€ million except %

Q4 2025

 

FY 2025

 

Sales

5.8

 

-31.6

 

Sales growth (%)

0.09%

 

-0.12%

 

Recurring Operating Income

 

 

-27

 

Recurring Net Income – Group share

 

 

-46

 

Breakdown by quarter of FY 2025 sales after application of IAS 29
FY 2025 sales correspond to the addition of:

  • Q4 2025 reported sales;

  • Q1, Q2 and Q3 2025 sales resulting from the application of IAS 29 until December 31, 2025, to sales of entities in hyperinflationary countries (application of the inflation rate until December 31, 2025, and translation into euros using the December 31, 2025, closing rate) and provided in the table below for information (unaudited data)

€ million

Q1 20251

Q2 20252

Q3 20253

Q4 2025

FY 2025

Europe

2,389

2,505

2,481

2,404

9,779

North America

1,633

1,546

1,577

1,560

6,316

China, North Asia & Oceania

936

1,080

1,032

904

3,953

Latin America

686

705

677

723

2,792

Asia, Middle East & Africa

1,172

1,071

1,108

1,093

4,444

 

 

 

 

 

 

Total

6,817

6,908

6,874

6,684

27,283

1Results from the application of IAS 29 until December 31, 2025, to Q1 sales of entities of hyperinflationary countries.
2Results from the application of IAS 29 until December 31, 2025, to Q2 sales of entities of hyperinflationary countries.
3Results from the application of IAS 29 until December 31, 2025, to Q3 sales of entities of hyperinflationary countries.

Definitions of geographical zones

Europe refers to European countries.

North America refers to the United States and Canada.

China, North Asia & Oceania refers to China, Japan, Australia and New Zealand.

Latin America refers to Mexico, Brazil, Argentina and Uruguay.

Asia, Middle East & Africa (AMEA) refers to Asia, Middle East including Turkey, Africa and CIS (zone previously called “Rest of the World”)

Financial indicators not defined in IFRS

Due to rounding, the sum of values presented may differ from totals as reported. Such differences are not material.

Like-for-like changes in sales reflect Danone's organic performance and essentially exclude the impact of:

  • changes in consolidation scope, with indicators related to a given fiscal year calculated on the basis of the previous year's scope;

  • changes in applicable accounting principles;

  • changes in exchange rates, with both previous-year and current-year indicators calculated using the same exchange rate (the exchange rate used is a projected annual rate determined by Danone for the current year and applied to both previous and current years).

Since January 1, 2023, all countries with hyperinflationary economies are taken into account in like-for-like changes as follows: sales growth in excess of around 26% per year (a three-year average at 26% would generally trigger the application of hyperinflationary accounting as defined in IFRS) is now excluded from the like-for-like sales growth calculation.

Bridge from like-for-like data to reported data

(€ million except %)

2024 sales

Like-for-like change

Impact of changes
in scope of consolidation

Impact of changes in exchange rates & others incl. IAS 29

Contribution of hyperinflation

Reported change

2025 sales

 

 

 

 

 

 

 

 

Q4

6,716

+4.7%

+0.8%

-6.3%

+0.4%

-0.5%

6,684

FY

27,376

+4.5%

-0.4%

-5.0%

+0.6%

-0.3%

27,283

Margin from operations is defined as the Gross margin over Sales ratio, where Gross margin corresponds to the difference between Sales and Industrial costs excluding reengineering initiatives and Logistics / Transportation costs.

Recurring operating income is defined as Danone’s operating income excluding Other operating income and expenses. Other operating income and expenses comprise items that, because of their significant or unusual nature, cannot be viewed as inherent to Danone’s recurring activity and have limited predictive value, thus distorting the assessment of its recurring operating performance and its evolution. These mainly include:

  • capital gains and losses on disposals of businesses and fully consolidated companies;

  • under IAS 36, impairment charges on intangible assets with indefinite useful lives;

  • costs related to strategic restructuring operations or transformation plans;

  • costs related to major external growth transactions;

  • costs related to crises and major disputes;

  • in connection with IFRS 3 and IFRS 10, (i) acquisition costs related to acquisitions of companies resulting in control, (ii) revaluation gains or losses accounted for following a loss of control, and (iii) changes in earn-outs subsequent to acquisitions resulting in control.

Recurring operating margin is defined as the Recurring operating income over Sales ratio.

Other non-recurring financial income and expense corresponds to financial income and expense items that, in view of their significant or unusual nature, cannot be considered as inherent to Danone’s recurring financial management. These notably include changes in the value of non-consolidated interests and profits or losses on the net monetary position.

Non-recurring income tax corresponds to income tax on non-recurring items as well as tax income and expense items that, in view of their significant or unusual nature, cannot be considered as inherent to Danone’s recurring performance.

Recurring effective tax rate measures the effective tax rate of Danone’s recurring performance and is computed as the ratio of income tax related to recurring items over recurring net income before tax.

Non-recurring share of profit (loss) of equity-accounted companies includes items that, because of their significant or unusual nature, cannot be viewed as inherent to the companies' recurring activity and thereby distort the assessment of their recurring performance and trends in that performance. These items mainly relate to:

  • capital gains and losses on disposals of Investments in equity-accounted companies;

  • impairment of investments in equity-accounted companies;

  • non-recurring items, as defined by Danone, included in the share of profit (loss) of equity-accounted companies.

Recurring net income (or Recurring net income – Group Share) corresponds to the Group share of the consolidated Recurring net income. The Recurring net income excludes items that, because of their significant or unusual nature, cannot be viewed as inherent to Danone’s recurring activity and have limited predictive value, thus distorting the assessment of its recurring performance and its evolution. Such non-recurring income and expenses correspond to Other operating income and expenses, Other non-recurring financial income and expenses, Non-recurring income tax, and Non-recurring share of profit (loss) of equity-accounted companies. These items, excluded from Net income, represent Non-recurring net income.

Recurring EPS (or Recurring net income – Group Share, per share after dilution) is defined as the ratio of Recurring net income adjusted for hybrid financing over Diluted number of shares. In compliance with IFRS, income used to calculate EPS is adjusted for the coupon related to the hybrid financing accrued for the period and presented net of tax.

 

FY 2024

 

FY 2025

 

Recurring

 

Total

 

Recurring

 

Total

 

Net income-Group share (€ million)

2,345

 

2,021

 

2,461

 

1,825

 

Coupon related to hybrid financing net of tax (€ million)

(4)

 

(4)

 

(8)

 

(8)

 

Number of shares

 

 

 

 

 

 

 

 

• Before dilution

643,283,916

 

643,283,916

 

643,127,462

 

643,127,462

 

• After dilution

644,436,743

 

644,436,743

 

645,130,545

 

645,130,545

 

EPS (€)

 

 

 

 

 

 

 

 

• Before dilution

3.64

 

3.14

 

3.81

 

2.82

 

• After dilution

3.63

 

3.13

 

3.80

 

2.82

 

Free cash flow represents cash flows provided or used by operating activities less capital expenditure net of disposals and, in connection with IFRS 3, excluding (i) acquisition costs related to acquisitions of companies resulting in control, and (ii) earn-outs related to acquisitions of companies resulting in control and paid subsequently to acquisition date.

(€ million)

FY 2024

FY 2025

Cash flows provided by operating activities

3,831

3,779

Capital expenditure

(923)

(1,055)

Disposal of property, plant and equipment and acquisition costs related to acquisitions of companies resulting in control1

95

74

Free cash flow

3,003

2,799

1 Represents acquisition costs related to acquisitions of companies resulting in control that were paid during the period

Working capital is defined as the net position between Current assets and Current liabilities. It reflects the resources required to finance the operating cycle, which corresponds to the average time between the acquisition of materials or services entering the production process and the final cash realization in accordance with IAS 1. Current assets mainly include items such as trade receivable and inventories, while Current liabilities mainly comprise trade payable, accrued expenses, and payroll‑related payables.

(€ million, except percentage)

December 31, 2024

December 31, 2025

Raw materials, work-in-progress and sundry supplies

1,291

1,204

Finished goods

1,215

1,325

Provisions for inventory write-downs

(229)

(205)

Inventories, net

2,277

2,325

Trade and other receivables from operations

3,035

3,152

Expected credit losses

(113)

(109)

Trade receivables, net

2,922

3,042

State and local authorities

976

802

Derivatives – assets1

60

46

Other

351

352

Total other current assets

1,387

1,200

TOTAL CURRENT ASSETS

6,586

6,567

 

 

 

Trade payables

(5,147)

(5,421)

Year-end discounts payable to customers

(1,482)

(1,618)

State and local authorities

(438)

(436)

Personnel costs, including social security charges

(1,283)

(1,322)

Derivatives – liabilities1

(79)

(60)

Other

(489)

(480)

Total other current liabilities2

(3,771)

(3,916)

TOTAL CURRENT LIABILITIES

(8,918)

(9,337)

WORKING CAPITAL

(2,332)

(2,770)

1 Fair value of derivatives used to hedge operating currency and commodity risks, most of which are set up for a period of less than one year.
2 Except Other current provisions.

Working capital/Sales ratio corresponds to the ratio of Working capital to Sales. It measures the level of resources invested in the operating cycle relative to the volume of activity achieved.

(€ million, except percentage)

December 31, 2024

December 31, 2025

Working capital

(2,332)

(2,770)

Sales

27,376

27,283

Working Capital as a percentage of consolidated sales

-8.5%

-10.2%

Net financial debt represents the net debt portion bearing interest. It corresponds to current and non-current financial debt (i) excluding Liabilities related to put options granted to non-controlling interests and earn-outs on acquisitions resulting in control and (ii) net of Cash and cash equivalents, Short term investments and Derivatives – assets managing net debt.

(€ million)

December 31, 2024

December 31, 2025

Non-current financial debt

10,175

10,074

Current financial debt

3,799

3,799

Short-term investments

(4,685)

(4,588)

Cash

(1,475)

(1,983)

Bank Overdraft

828

1,246

Derivatives — non-current assets1

(3)

(84)

Derivatives — current-assets1

(37)

(33)

Net debt

8,601

8,431

  • Liabilities related to put options granted to non-controlling interests — non-current

-

(49)

  • Liabilities related to put options granted to non-controlling interests and earn-outs on acquisitions resulting in control — current

(317)

(323)

Net financial debt

8,285 

8,059

1 Managing net debt only

The net debt/EBITDA ratio corresponds to the ratio of net debt to operating income restated for depreciation, amortization and impairment of tangible and intangible assets. The ratio for 2025 fiscal year is 2.0x:

(€ million, except ratio)

2024

2025

Net debt as of December 31

8,601

8,431

Operating income

3,379

2,940

Depreciation, amortization and impairment of property, plant and equipment and intangible assets

1,168

1,355

EBITDA of the year

4,546

4,295

Net Debt / EBITDA of the year

1.9x

2.0x

ROIC is the ratio of net operating income in the current year to average capital invested in the current and prior years.

Invested capital = goodwill and other tangible and intangible assets + investments in non-consolidated companies and other financial investments + assets held for sale net of liabilities + working capital requirements - provisions and other net liabilities.

(€ million, except percentage)

2023

2024

2025

Recurring operating income

3,481

3,558

3,665

Recurring income tax rate

27.2%

27.3%

27.0%

Tax on recurring operating income

(947)

(971)

(990)

Recurring income from equity-accounted companies

55

76

108

OPERATING INCOME

2,588

2,662

2,783

 

 

 

 

Intangible assets

23,093

24,009

23,136

Property, plant and equipment

6,441

6,519

6,445

GOODWILL AND OTHER TANGIBLE AND INTANGIBLE ASSETS

29,534

30,527

29,581

Investments in equity-accounted companies

416

584

730

Other financial investments

839

864

913

Short-term loans

3

2

2

INVESTMENTS IN NON-CONSOLIDATED COMPANIES AND OTHER FINANCIAL INVESTMENTS

1,259

1,449

1,645

Assets held for sale net of liabilities

286

28

Deferred taxes net of deferred tax assets

(743)

(952)

(927)

Provisions for retirement and other long-term benefits

(904)

(900)

(771)

Other non-current provisions and liabilities

(1,303)

(1,152)

(1,171)

PROVISIONS AND OTHER NET LIABILITIES

(2,950)

(3,003)

(2,869)

Working capital

(1,686)

(2,333)

(2,770)

Invested capital of the year

26,443

26,641

25,611

AVERAGE INVESTED CAPITAL

27,271

26,542

26,124

ROIC

9.5%

10.0%

10.7%

o o O o o

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements concerning Danone that are subject to risks and uncertainties. In some cases, you can identify these forward-looking statements by forward-looking words, such as “estimate”, “expect”, “anticipate”, “project”, “plan”, “intend”, “objective”, “believe”, “forecast”, “guidance”, “foresee”, “likely”, “may”, “should”, “goal”, “target”, “might”, “will”, “could”, “predict”, “continue”, “convinced” and “confident,” the negative or plural of these words and other comparable terminology, or by using future dates. Forward looking statements in this document include, but are not limited to, predictions of future activities, operations, direction, performance and results of Danone.

These forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the “Risk Factors” section of Danone’s Universal Registration Document (the current version of which is available at www.danone.com).

Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities.

The presentation to analysts and investors will be broadcast live today from 8:00 a.m. (Paris time)
on Danone’s website (www.danone.com).
Related slides will also be available on the website in the Investors section.

APPENDIX – Sales by geographical zone and by category

Reported, in € million

Q1

Q2

Q3

Q4

FY

 

 

 

 

2024

2025

2024

2025

2024

2025

2024

2025

2024

2025

 

 

 



BY GEOGRAPHICAL ZONE

 

 

 

 

 

 

 

 

 

 

 

 

Europe

2,336

2,389

2,447

2,505

2,427

2,481

2,358

2,404

9,568

9,779

 

 

 

North America

1,737

1,633

1,595

1,546

1,611

1,577

1,636

1,560

6,579

6,316

 

 

 

China, North Asia & Oceania

840

936

1,001

1,080

967

1,032

886

904

3,694

3,953

 

 

 

Latin America

727

715

810

714

706

676

724

723

3,029

2,792

 

 

 

Asia, Middle East & Africa

1,150

1,170

1,084

1,067

1,115

1,111

1,112

1,093

4,506

4,444

 

 

 



BY CATEGORY

 

 

 

 

 

 

 

 

 

 

 

EDP

3,474

3,381

3,298

3,261

3,283

3,255

3,355

3,288

13,463

13,158

 

 

 

Specialized Nutrition

2,183

2,306

2,213

2,307

2,189

2,299

2,308

2,372

8,936

9,277

 

 

 

Waters

1,132

1,156

1,426

1,345

1,354

1,322

1,053

1,023

4,977

4,848

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL

6,789

6,844

6,938

6,913

6,826

6,876

6,716

6,684

27,376

27,283

 

 

 


 

Q1 2025

Q2 2025

Q3 2025

Q4 2025

FY 2025

 

 

Reported change

LFL change

Reported change

LFL change

Reported change

LFL change

Reported change

LFL change

Reported change

LFL change

 



BY GEOGRAPHICAL ZONE

 

 

 

 

 

 

 

 

 

 

 

 

Europe

+2.3%

+2.0%

+2.4%

+2.2%

+2.2%

+2.6%

+1.9%

+2.5%

+2.2%

+2.3%

 

North America

-5.9%

+3.7%

-3.0%

+2.3%

-2.1%

+1.5%

-4.7%

+0.7%

-4.0%

+2.0%

 

China, North Asia & Oceania

+11.5%

+9.9%

+7.9%

+12.4%

+6.7%

+13.8%

+2.1%

+10.4%

+7.0%

+11.7%

 

Latin America

-1.6%

+9.0%

-11.9%

+2.9%

-4.2%

+4.3%

-0.1%

+8.3%

-7.8%

+6.0%

 

Asia, Middle East & Africa

+1.7%

+3.3%

-1.6%

+4.1%

-0.4%

+6.8%

-1.7%

+8.3%

-1.4%

+5.6%

 



BY CATEGORY

 

 

 

 

 

 

 

 

 

 

 

EDP

-2.7%

+3.7%

-1.1%

+3.0%

-0.9%

+3.5%

-2.0%

+3.8%

-2.3%

+3.5%

 

Specialized Nutrition

+5.7%

+5.3%

+4.2%

+8.7%

+5.0%

+8.3%

+2.8%

+7.2%

+3.8%

+7.4%

 

Waters

+2.2%

+4.1%

-5.7%

-0.5%

-2.3%

+2.3%

-2.8%

+2.2%

-2.6%

+1.9%

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL

+0.8%

+4.3%

-0.4%

+4.1%

+0.7%

+4.8%

-0.5%

+4.7%

-0.3%

+4.5%

 

Disclaimer: This press release presents the results for the full year 2025 from the consolidated financial statements of Danone as of December 31, 2025 (unaudited). Regarding the audit process, as of today, the Statutory Auditors have substantially completed their examination of financial statements and verification of the sustainability information.

CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Consolidated income statement and earnings per share (unaudited)

 

 

Year ended December 31

(in € millions except earnings per share in €)

 

2024

2025

Sales

 

27,376

27,283

 

 

 

 

Cost of goods sold

 

(13,769)

(13,473)

Selling expense

 

(6,572)

(6,568)

General and administrative expense

 

(2,928)

(2,996)

Research and Development expense

 

(447)

(479)

Other income (expense)

 

(102)

(102)

Recurring operating income

 

3,558

3,665

 

 

 

 

Other operating income (expense)

 

(179)

(725)

Operating income

 

3,379

2,940

 

 

 

 

Interest income on cash equivalents and short-term investments

 

403

301

Financial interest on debt

 

(600)

(498)

Cost of net financial debt

 

(197)

(197)

Other financial income

 

41

42

Other financial expense

 

(224)

(249)

Income before tax

 

2,999

2,536

 

 

 

 

Income tax

 

(929)

(741)

Net income from fully consolidated companies

 

2,070

1,795

 

 

 

 

Share of profit (loss) of equity-accounted companies

 

30

92

NET INCOME

 

2,100

1,887

 

 

 

 

Net income – Group share

 

2,021

1,825

Net income – Non-controlling interests

 

79

63

 

 

 

 

Earnings per share – Group share

 

3.14

2.82

Diluted earnings per share – Group share

 

3.13

2.82

Consolidated balance sheet (unaudited)

 

 

As of December 31

(in € millions)

 

2024

2025

ASSETS

 

 

 

 

 

 

 

Goodwill

 

18,062

17,275

Brands

 

5,390

5,242

Other intangible assets

 

556

619

Intangible assets

 

24,009

23,136

Property, plant and equipment

 

6,519

6,445

Investments in equity-accounted companies

 

583

730

Investments in other non-consolidated companies

 

325

278

Long-term loans and financial assets

 

538

634

Other financial assets

 

864

913

Derivatives – assets

 

3

84

Deferred taxes

 

528

534

Non-current assets

 

32,505

31,842

 

 

 

 

Inventories

 

2,277

2,325

Trade receivables

 

2,922

3,042

Other current assets

 

1,387

1,200

Short-term loans

 

2

2

Derivatives – assets

 

37

33

Short-term investments

 

4,685

4,588

Cash

 

1,475

1,983

Assets held for sale

 

56

Current assets

 

12,786

13,229

 

 

 

 

TOTAL ASSETS

 

45,292

45,071


 

 

As of December 31

(in € millions)

 

2024

2025

EQUITY AND LIABILITIES

 

 

 

 

 

 

 

Share capital

 

170

170

Additional paid-in capital

 

5,331

5,420

Retained earnings and other

 

17,546

18,581

Translation adjustments

 

(3,134)

(4,676)

Accumulated other comprehensive income

 

(592)

(600)

Treasury shares

 

(1,527)

(1,978)

Equity – Group share

 

17,795

16,917

Non-controlling interests

 

59

52

Consolidated equity

 

17,853

16,970

 

 

 

 

Financing

 

9,929

9,761

Derivatives – liabilities

 

246

202

Liabilities related to put options granted to non-controlling interests

 

110

Non-current financial debt

 

10,175

10,074

Provisions for retirement obligations and other long-term benefits

 

900

771

Deferred taxes

 

1,480

1,461

Other provisions and non-current liabilities

 

1,152

1,171

Non-current liabilities

 

13,707

13,476

 

 

 

 

Financing

 

4,291

4,658

Derivatives – liabilities

 

19

61

Liabilities related to put options granted to non-controlling interests and earn‑outs on acquisitions resulting in control

 

317

326

Current financial debt

 

4,627

5,045

Trade payables

 

5,147

5,421

Other provisions and current liabilities

 

3,957

4,131

Liabilities directly associated with assets held for sale

 

28

Current liabilities

 

13,732

14,625

TOTAL EQUITY AND LIABILITIES

 

45,292

45,071

Consolidated statement of cash flows (unaudited)

 

 

Year ended December 31

(in € millions)

 

2024

2025

Net income

 

2,100

1,887

Share of profit (loss) of equity-accounted companies, net of dividends received

 

(7)

(68)

Depreciation, amortization and impairment of property, plant and equipment and intangible assets

 

1,168

1,355

Net change in provisions and liabilities

 

(21)

54

Change in deferred taxes

 

61

(60)

(Gains) losses on disposal of property, plant and equipment and financial investments

 

(225)

(1)

Expense related to share-based payments and Company Savings Plans

 

71

109

Cost of net financial debt

 

196

195

Net interest paid

 

(167)

(169)

Net change in interest income (expense)

 

29

25

Other items with no cash impact

 

122

202

Cash flows provided by operating activities, before changes in net working capital

 

3,297

3,503

(Increase) decrease in inventories

 

50

(192)

(Increase) decrease in trade receivables

 

(7)

(328)

Increase (decrease) in trade payables

 

353

527

Change in other receivables and payables

 

137

268

Change in working capital requirements

 

534

276

Cash flows provided by operating activities

 

3,831

3,779

Capital expenditure

 

(923)

(1,055)

Proceeds from the disposal of property, plant and equipment

 

18

44

Net cash outflows on purchases of subsidiaries and financial investments

 

(153)

(858)

Net cash inflows on disposal of subsidiaries and financial investments

 

507

106

(Increase) decrease in long-term loans and other long-term financial assets

 

87

(9)

Cash flows provided by (used in) investment activities

 

(463)

(1,773)

Increase in share capital and additional paid-in capital

 

76

89

Purchase of treasury shares (net of disposals)

 

(486)

Net issuance of undated subordinated notes

 

498

Interest expense and redemption premium on undated subordinated notes

 

(5)

(5)

Dividends paid to Danone shareholders

 

(1,348)

(1,379)

Buyout of non-controlling interests

 

(1)

Dividends paid to non-controlling interests

 

(108)

(82)

Contribution from non-controlling interests to capital increases

 

1

(1)

Transactions with non-controlling interests

 

(108)

(84)

Bonds issued during the period

 

1,397

1,666


 

 

Year ended December 31

(in € millions)

 

2024

2025

Bonds redeemed during the period

 

(2,006)

(2,050)

Net cash flows from other current and non-current financial debt

 

(808)

82

Net cash flows from short-term investments

 

(1,015)

61

Cash flows provided by (used in) financing activities

 

(3,817)

(1,610)

Effect of exchange rate and other changes

 

(2)

(307)

INCREASE IN CASH

 

(452)

90

 

 

 

 

Net cash as of January 1

 

1,099

647

Net cash as of December 31

 

647

737

 

 

 

 

ADDITIONAL INFORMATION

 

 

 

Income tax payments during the year

 

(766)

(697)


All references in this document to Like-for-like (LFL) changes, Recurring operating income and margin, Margin from operations, Non-recurring operating income and expenses, Recurring net income, Recurring income tax rate, Recurring EPS, Free cash flow, Net financial debt, ROIC, Net debt/EBITDA ratio and Working capital/sales ratio correspond to alternative performance measures not defined by IFRS. Their definitions, as well as their reconciliation with financial statements, are listed on pages 6 to 11.

Attachment